Our Leadership
A Team of Passionate Leaders
Kymera is led by a seasoned team of established biopharmaceutical leaders with the insights and experience to accelerate our progress and change patient lives.
Join Our Exceptional Team
We welcome like-minded pioneers to join us on our extraordinary journey as we create a culture where diverse perspectives are invited and collaboration is celebrated—all in service of our goal to revolutionize medicine and change patients’ lives.
Management Team
Kymera’s leadership are all dedicated innovators, each with decades of experience in drug discovery, development, and growing companies.
No Results Found
Board of Directors
Our board is composed of leaders with the experience and perspective to support Kymera’s evolution as we work to improve patients’ lives.
No Results Found
Join Us on Our Mission
We are a team of pioneers dedicated to reinventing the treatment of human disease and reshaping the landscape of healthcare.
Company Stats
Kymera is building a fully integrated medicines company to redefine disease treatment.
90%
of employees take pride in working at Kymera
500+
issued or pending patents
>$1.5B
capital raised to advance our pipeline
1st
degrader targeting immunological diseases in clinical studies
Our Leadership is Driving the Field Forward
Kymera’s team is catalyzing progress in the science of TPD with key publications and presentations that unlock insights and showcase our findings.
September 17, 2025
KT-621, an Oral, Once Daily, Targeted STAT6 Degrader: First-in-Human Phase 1a Safety, Pharmacokinetics, Pharmacodynamics and Th2 Biomarker Effects
European Academy of Dermatology & Venereology (EADV) 2025 – Late Breaking Presentation
October 27, 2025
Potent and Selective Oral IRF5 Degrader, KT-579, Demonstrates In Vitro and In Vivo Activity Comparable or Superior to Approved or Clinically Active Agents in Human Cellular Assays and Lupus Efficacy Models
American College of Rheumatology (ACR) 2025